Skip to main content
Fig. 2 | Cost Effectiveness and Resource Allocation

Fig. 2

From: Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

Fig. 2

a Predicted PFS*, b OS for Ceritinib and Crizotinib under HR Method, *The predicted PFS curve for ceritinib was based on exponential functions. PFS curve for crizotinib was derived by applying HRs to the corresponding curve for ceritinib. The predicted OS curve for ceritinib was based on exponential functions. OS curve crizotinib was derived by applying HRs to the corresponding curve for ceritinib. HR, hazard ratio; PFS, progression-free survival; OS, overall survival

Back to article page